Top Markets
#1 QuantixAI QuantixAI +105.36%
#2 龙虾 (Lobster) 龙虾 (Lobster) +36.43%
#3 MetaDAO MetaDAO +28.82%
#4 Rain Rain +23.15%
#5 Pons Pons +19.66%
#6 Bedrock Bedrock +18.87%
#7 Prom Prom +18.28%
#8 DOG•GO•TO•THE•MOON (Runes) DOG•GO•TO•THE•MOON (Runes) +17.63%
#9 Wrapped STX (Velar) Wrapped STX (Velar) +17.19%
#10 Ontology Gas Ontology Gas +15.31%
Coin of the day
QuantixAI QuantixAI
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Gracell Biotechnologies Inc. Gracell Biotechnologies Inc.

Gracell Biotechnologies Inc.

GRCL
Classement en actions #20198
Gracell Biotechnologies Inc. is a clinical-stage biopharmaceutical company... Gracell Biotechnologies Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of cell-based therapies, primarily for cancer treatment, within the People's Republic of China. The company's leading investigational therapies include: GC012F: A FasTCAR-enhanced autologous CAR-T product designed to target both BCMA and CD19, currently undergoing Phase I clinical trials for multiple myeloma. GC019F: A FasTCAR-enabled CD19-directed autologous CAR-T therapy, which is progressing through Phase I trials for adult B-cell acute lymphoblastic leukemia (B-ALL) and is also in preclinical development for relapsed or refractory (r/r) B cell non-Hodgkin's lymphoma (B-NHL). GC027: A TruUCAR-powered allogeneic CAR-T product targeting CD7, presently in Phase I clinical development for adult T-cell acute lymphoblastic leukemia. Additionally, Gracell's pipeline features: GC007g: A donor-derived allogeneic CAR-T cell therapy directed at CD19, currently in a Phase 1/2 registrational study for r/r B-ALL. GC502: An off-the-shelf, TruUCAR-enabled allogeneic CAR-T candidate engineered to target both CD19 and CD7, which is in Phase I trials for B-cell malignancies. Beyond these, Gracell maintains a broader portfolio of earlier-stage therapeutic candidates addressing diverse oncological conditions, including ovarian cancer, breast cancer, peripheral T cell lymphoma (a subtype of NHL), and T cell lymphoblastic leukemia. Established in 2017, the company's headquarters are situated in Suzhou, China.
Prix de l'action
$10.25
Dernière synchronisation: 2024-02-22
Capitalisation boursière
$137.83M
Changement (1 jour)
0.00%
Changement (1 an)
0.00%
Pays
CN
Échange Gracell Biotechnologies Inc. (GRCL)

Catégorie

Healthcare
Bénéfices pour Gracell Biotechnologies Inc. (GRCL)
Bénéfices en 2026 TTM : 0
Selon les derniers rapports financiers de Gracell Biotechnologies Inc., les bénéfices actuels de l'entreprise sont de 0. En 2026, l'entreprise a réalisé un bénéfice de 0, égal à celui de 2026 qui était de 0. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour Gracell Biotechnologies Inc. de 2026 à 2026
Bénéfices à la fin de chaque année
Année Bénéfices Changez
Pas assez de données pour les dates fournies.
Bénéfices des entreprises similaires ou concurrentes
Entreprise Bénéfices Différence de bénéfices Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH